Impaired Cardiac AMPK (5'-Adenosine Monophosphate-Activated Protein Kinase) and Ca2+-Handling, and Action Potential Duration Heterogeneity in Ibrutinib-Induced Ventricular Arrhythmia Vulnerability

J Am Heart Assoc. 2024 Jun 18;13(12):e032357. doi: 10.1161/JAHA.123.032357. Epub 2024 Jun 6.

Abstract

Background: We recently demonstrated that acute administration of ibrutinib, a Bruton's tyrosine kinase inhibitor used in chemotherapy for blood malignancies, increases ventricular arrhythmia (VA) vulnerability. A pathway of ibrutinib-induced vulnerability to VA that can be modulated for cardioprotection remains unclear.

Methods and results: The effects of ibrutinib on cardiac electrical activity and Ca2+ dynamics were investigated in Langendorff-perfused hearts using optical mapping. We also conducted Western blotting analysis to evaluate the impact of ibrutinib on various regulatory and Ca2+-handling proteins in rat cardiac tissues. Treatment with ibrutinib (10 mg/kg per day) for 4 weeks was associated with an increased VA inducibility (72.2%±6.3% versus 38.9±7.0% in controls, P<0.002) and shorter action potential durations during pacing at various frequencies (P<0.05). Ibrutinib also decreased heart rate thresholds for beat-to-beat duration alternans of the cardiac action potential (P<0.05). Significant changes in myocardial Ca2+ transients included lower amplitude alternans ratios (P<0.05), longer times-to-peak (P<0.05), and greater spontaneous intracellular Ca2+ elevations (P<0.01). We also found lower abundance and phosphorylation of myocardial AMPK (5'-adenosine monophosphate-activated protein kinase), indicating reduced AMPK activity in hearts after ibrutinib treatment. An acute treatment with the AMPK activator 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside ameliorated abnormalities in action potential and Ca2+ dynamics, and significantly reduced VA inducibility (37.1%±13.4% versus 72.2%±6.3% in the absence of 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside, P<0.05) in hearts from ibrutinib-treated rats.

Conclusions: VA vulnerability inflicted by ibrutinib may be mediated in part by an impairment of myocardial AMPK activity. Pharmacological activation of AMPK may be a protective strategy against ibrutinib-induced cardiotoxicity.

Keywords: AMPK; action potential; calcium handling; ibrutinib; ventricular arrhythmias.

MeSH terms

  • AMP-Activated Protein Kinases* / metabolism
  • Action Potentials* / drug effects
  • Adenine* / analogs & derivatives
  • Adenine* / pharmacology
  • Animals
  • Arrhythmias, Cardiac* / chemically induced
  • Arrhythmias, Cardiac* / metabolism
  • Arrhythmias, Cardiac* / physiopathology
  • Arrhythmias, Cardiac* / prevention & control
  • Calcium / metabolism
  • Calcium Signaling / drug effects
  • Disease Models, Animal
  • Heart Rate / drug effects
  • Isolated Heart Preparation
  • Male
  • Myocytes, Cardiac / drug effects
  • Myocytes, Cardiac / enzymology
  • Myocytes, Cardiac / metabolism
  • Myocytes, Cardiac / pathology
  • Piperidines* / pharmacology
  • Protein Kinase Inhibitors / pharmacology
  • Pyrazoles* / pharmacology
  • Pyrimidines* / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Time Factors

Substances

  • ibrutinib
  • Adenine
  • Piperidines
  • Pyrimidines
  • AMP-Activated Protein Kinases
  • Pyrazoles
  • Protein Kinase Inhibitors
  • Calcium